A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60 mg administered every 28 days for 6 months in acromegalic patients with uncontrolled disease
Active, not recruiting
- Conditions
- Treatment of acromegalic patients partially responsive to somatostatin analoguesMedDRA version: 6.1Level: PTClassification code 10000599
- Registration Number
- EUCTR2005-003444-53-IT
- Lead Sponsor
- OVARTIS FARMA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method